Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PRHSX vs. GGHCX: which is better?

Bottom line

PRHSX vs GGHCX: the short answer

PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 59% by weight.

But PRHSX is far broader, holding 279 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.

PRHSX is cheaper at 0.83% vs 1.07% — a difference of $24 a year per $10,000 invested.

Over five years, PRHSX returned +4.2% a year vs +2.6% for GGHCX.

GGHCX has a front-end sales load of up to 5.5%; the other does not.

Updated Nov 19, 2026

PRHSX vs GGHCX side by side

PRHSXGGHCX
TypeMutual fundMutual fund
Fund familyT. Rowe PriceInvesco
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.83%1.07%
Annual cost per $10k$83$107
10-yr cost on $10k (prospectus)$1,025$1,784
Max front load—5.5%
12b-1 fee—0.25%
1-yr return+17.7%+9.2%
5-yr return (annualized)+4.2%+2.6%
10-yr return (annualized)+9.1%+5.8%
Best quarter+23.5%+19.6%
Worst quarter−15.8%−16.5%
Net assets (fund)$11.9B$1.2B
Number of holdings27982
Portfolio turnover62%59%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPRHSXGGHCXDifference
2025+17.7%+15.5%+2.2%
2024+1.8%+4.0%−2.2%
2023+3.1%+3.1%+0.0%
2022−12.2%−13.5%+1.3%
2021+13.3%+12.2%+1.1%
2020+30.1%+14.5%+15.7%
2019+29.1%+32.0%−2.9%
2018+1.2%+0.5%+0.8%
2017+28.0%+15.5%+12.5%
2016−10.4%−11.7%+1.4%

Source: Fund prospectus bar charts

Holdings overlap

12 of PRHSX's top 25 holdings also appear in GGHCX's top 25.

Shared top holdings
HoldingPRHSXGGHCX
Eli Lilly & Co14.28%10.59%
Johnson & Johnson6.63%6.76%
Unitedhealth Group Inc5.99%6.17%
Abbvie Inc5.10%4.03%
Merck & Co. Inc.4.01%4.59%
Gilead Sciences Inc2.82%3.63%
Thermo Fisher Scientific Inc2.52%1.55%
Vertex Pharmaceuticals Inc2.28%2.01%
Guardant Health Inc1.23%2.04%
Cardinal Health Inc1.03%2.10%
Cvs Health Corp0.94%2.52%
Brightspring Health Services0.82%2.20%

Source: SEC Form N-PORT

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

GGHCX top 10

  1. Eli Lilly and Co. — 10.59%
  2. Johnson & Johnson — 6.76%
  3. UnitedHealth Group Inc. — 6.17%
  4. Invesco Private Prime Fund — 4.67%
  5. Merck & Co., Inc. — 4.59%
  6. AbbVie Inc. — 4.03%
  7. Gilead Sciences, Inc. — 3.63%
  8. argenx SE — 3.24%
  9. CVS Health Corp. — 2.52%
  10. Welltower Inc. — 2.34%

FAQ

What is the difference between PRHSX and GGHCX?
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 59% by weight. But PRHSX is far broader, holding 279 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.
Which is cheaper, PRHSX or GGHCX?
PRHSX has the lower expense ratio (0.83%).
Should I own both PRHSX and GGHCX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.